Abstract
Background
Rituximab, a chimeric anti-CD20 monoclonal antibody, is an effective treatment in steroid-dependent nephrotic syndrome (SDNS). However, some patients develop adverse reactions.
Case-Diagnosis/Treatment
Patient 1, a 14-year-old boy with SDNS since the age of 2, was treated with oral prednisone, cyclosporine A (CsA) and mycophenolate mofetil. A first infusion of rituximab at age 12 years was well tolerated, but this was followed by a prolonged relapse unresponsive to oral prednisone, mycophenolate mofetil and CsA. A second rituximab infusion was attempted, but treatment was interrupted due to severe dyspnea. Treatment with a humanized anti-CD20 monoclonal antibody, ofatumumab, was then attempted. The patient experienced a mild allergic reaction and maintained remission despite interruption of all treatment at >12 months of follow-up. Patient 2, a 3-year-old boy who presented at 18 months with nephrotic syndrome initially resistant to treatment with oral prednisone, was given with three intravenous boluses of methylprednisolone followed by CsA and achieved remission. Upon steroid discontinuation, the NS relapsed. Prednisone was restarted and treatment with a single dose of rituximab was never completed due to a severe allergic reaction. Ofatumumab infusion was uneventful, and he maintained remission during the follow-up period (>12 months) despite interruption of prednisone therapy. B cells reappeared at 7 months in both patients.
Conclusions
Ofatumumab may be a therapeutic option in severe forms of NS with allergy to rituximab.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Iijima K, Sako M, Nozu K, Mori R, Tuchida N, Kamei K, Miura K, Aya K, Nakanishi K, Ohtomo Y, Takahashi S, Tanaka R, Kaito H, Nakamura H, Ishikura K, Ito S, Ohashi Y, Rituximab for Childhood-onset Refractory Nephrotic Syndrome (RCRNS) Study Group (2014) Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 384:1273–1281
Ravani P, Rossi R, Bonanni A, Quinn RR, Sica F, Bodria M, Pasini A, Montini G, Edefonti A, Belingheri M, De Giovanni D, Barbano G, Degl’Innocenti L, Scolari F, Murer L, Reiser J, Fornoni A, Ghiggeri GM (2015) Rituximab in children with steroid-dependent nephrotic syndrome: a multicenter, open-label, noninferiority, randomized controlled trial. J Am Soc Nephrol 26:2259–2266
Safdar OY, Aboualhameael A, Kari JA (2014) Rituximab for troublesome cases of childhood nephrotic syndrome. World J Clin Pediatr 3:69–75
Kamei K, Ogura M, Sato M, Sako M, Iijima K, Ito S (2016) Risk factors for relapse and long-term outcome in steroid-dependent nephrotic syndrome treated with rituximab. Pediatr Nephrol 31:89–95
Elie V, Fakhoury M, Deschenes G, Jacqz-Aigrain E (2012) Physiopathology of idiopathic nephrotic syndrome: lessons from glucocorticoids and epigenetic perspectives. Pediatr Nephrol 27:1249–1256
Lombel RM, Gipson DS, Hodson EM, Kidney Disease: Improving Global Outcomes (2013) Treatment of steroid-sensitive nephrotic syndrome: new guidelines from KDIGO. Pediatr Nephrol 28:415–426
Ehrich JH, Geerlings C, Zivicnjak M, Franke D, Geerlings H, Gellermann J (2007) Steroid-resistant idiopathic childhood nephrosis: overdiagnosed and undertreated. Nephrol Dial Transplant 22:2183–2193
Johnson PW, Glennie MJ (2001) Rituximab: mechanisms and applications. Br J Cancer 85:1619–1623
Basu B (2014) Ofatumumab for rituximab-resistant nephrotic syndrome. N Engl J Med 370:1268–1270
Bonanni A, Rossi R, Murtas C, Ghiggeri GM (2015) Low-dose ofatumumab for rituximab-resistant nephrotic syndrome. BMJ Case Rep. doi:10.1136/bcr-2015-210208
Ram R, Ben-Bassat I, Shpilberg O, Polliack A, Raanani P (2009) The late adverse events of rituximab therapy—rare but there! Leuk Lymphoma 50:1083–1095
Albert D, Dunham J, Khan S, Stansberry J, Kolasinski S, Tsai D, Pullman-Mooar S, Barnack F, Striebich C, Looney RJ, Prak ET, Kimberly R, Zhang Y, Eisenberg R (2008) Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus. Ann Rheum Dis 67:1724–1731
Zhang B (2009) Ofatumumab. Mabs 1:326–331
Frustaci AM, Tedeschi A, Picardi P, Cairoli R, Montillo M (2015) Clinical utility and patient considerations in the use of ofatumumab in chronic lymphocytic leukemia. Biologics 9:75–86
Colucci M, Carsetti R, Cascioli S, Casiraghi F, Perna A, Rava L, Ruggiero B, Emma F, Vivarelli M (2015) B cell reconstitution after rituximab treatment in idiopathic nephrotic syndrome. J Am Soc Nephrol 27:1811–1822
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Rights and permissions
About this article
Cite this article
Vivarelli, M., Colucci, M., Bonanni, A. et al. Ofatumumab in two pediatric nephrotic syndrome patients allergic to rituximab. Pediatr Nephrol 32, 181–184 (2017). https://doi.org/10.1007/s00467-016-3498-y
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00467-016-3498-y